Versant Venture Capital V L.P. 13D and 13G filings for Repare Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-01-06 4:19 pm Sale |
2022-12-29 | 13D | Repare Therapeutics Inc. RPTX |
Versant Venture Capital V L.P. | 2,094,451 5.000% |
-250,000 (-10.66%) |
Filing |
| 2022-06-13 4:38 pm Sale |
2022-06-03 | 13D | Repare Therapeutics Inc. RPTX |
Versant Venture Capital V L.P. | 2,344,451 5.600% |
-250,000 (-9.64%) |
Filing |
| 2021-08-16 4:57 pm Unchanged |
2021-08-05 | 13D | Repare Therapeutics Inc. RPTX |
Versant Venture Capital V L.P. | 2,594,451 7.000% |
0 (Unchanged) |
Filing |
| 2021-02-26 4:36 pm Sale |
2021-02-16 | 13D | Repare Therapeutics Inc. RPTX |
Versant Venture Capital V L.P. | 2,594,451 7.100% |
-550,000 (-17.49%) |
Filing |
| 2021-01-25 4:27 pm Sale |
2021-01-14 | 13D | Repare Therapeutics Inc. RPTX |
Versant Venture Capital V L.P. | 3,144,451 8.600% |
-275,000 (-8.04%) |
Filing |
| 2020-07-06 9:31 pm Purchase |
2020-06-23 | 13D | Repare Therapeutics Inc. RPTX |
Versant Venture Capital V L.P. | 3,419,451 9.300% |
3,419,451 (New Position) |
Filing |